- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT00981773
The St. Marys and The Mater Switch Study (SMASH)
A Prospective, Randomised Study to Assess Safety, Changes in Platelet Reactivity, Plasma Cardiac Biomarkers, Immunological and Metabolic Parameters in HIV-1 Infected Subjects Undergoing a Switch in Antiretroviral Therapy
The aim of the study is to determine whether switching from an antiretroviral regimen containing abacavir and/or didanosine to one containing maraviroc will lead to a reduction in platelet reactivity and inflammatory markers at weeks 12 and 24 thereby conferring a reduction in cardiac risk.
In addition the study will assess the efficacy of a maraviroc containing regimen in combination with a boosted protease inhibitor in terms of tolerability and achieving long term viral suppression as assessed at week 48.
The investigators hypothesize that there will be a rapid reduction in platelet reactivity on switching to maraviroc and that a boosted protease inhibitor in combination with maraviroc will provide a safe and efficacious antiretroviral regimen enabling a reduction in cardiac risk whilst maintaining virological suppression.
Studienübersicht
Status
Bedingungen
Intervention / Behandlung
Detaillierte Beschreibung
To assess the safety, changes in platelet reactivity, plasma cardiac biomarkers and metabolic parameters in HIV 1 infected subjects undergoing a switch in ART from a nucleoside containing regimen which includes abacavir and / or didanosine to a maraviroc containing regimen.
40 HIV-1 infected subjects currently receiving stable antiretroviral therapy consisting of a boosted protease inhibitor and two NRTIs including abacavir and / or didanosine will be recruited. Subjects will be randomized on a 1:1 basis to one of two arms:
Arm 1 (immediate switch in antiretroviral therapy)
- Continue current boosted protease inhibitor
- Switch NRTI backbone to maraviroc 150 mg bid
Arm 2 (continue current antiretroviral therapy)
- No change to current antiretroviral therapy for twelve weeks
- After twelve weeks switch therapy as per Arm 1
Subjects will be followed up for 48 weeks and will attend for clinic visits at screening, baseline, weeks 4, 12, 16, 24, 36 and 48. Platelet reactivity, inflammatory and cardiac biomarkers and markers of T cell activation will be assessed at baseline, week 12 and week 24.
Following completion of the study subjects may continue their study antiretroviral regimen or switch to an alternative regimen at their clinician's discretion.
Inclusion Criteria
- HIV-1 infected males or females
- Between 18 and 65 years of age
- Signed informed consent
Currently receiving a stable antiretroviral regimen comprising of:
- two licensed NRTIs including abacavir and/or didanosine
- any licensed boosted protease inhibitor at any dose (excluding tipranavir*)
- Undetectable plasma HIV RNA to less than 50 copies/mL for at least 24 weeks prior to screening
- Availability of stored plasma with which to perform a tropism assay
- CCR5 tropic HIV virus based on a tropism assay from a stored plasma sample
- Willing to continue unchanged, or to modify antiretroviral therapy, in accordance with the randomisation assignment
- No documented viral resistance to currently licensed HIV-1 protease inhibitors based either on previous HIV-1 genotypic resistance testing or in the judgement of the study investigators
- No previous exposure to maraviroc or CCR5 receptor antagonists
- Subjects in good health upon medical history, physical exam, and laboratory testing in the opinion of the investigator
Female subjects who are heterosexually active and of childbearing potential (i.e., not surgically sterile or at least two years post menopausal) must avoid becoming pregnancy as follows from screening through completion of the study using one or both of the following methods:
- barrier contraceptives (condom, diaphragm with spermicide)
- IUD PLUS a barrier contraceptive
- Female subjects of childbearing potential must have a negative pregnancy test. Exclusion criteria
- failure of current antiretroviral regimen due to virological failure
- active opportunistic infection, malignancy or significant co-morbidities in the opinion of the investigator
- pregnancy
- current prohibited concomitant medication (as listed in section 4.1.4)
- no available stored plasma sample predating their current antiretroviral regimen upon which a tropism assay can be performed
- active HBV infection as evidenced by positive hepatitis B surface antigen
- active hepatitis C virus infection as evidenced by positive HCV PCR or HCV antibody
Studientyp
Einschreibung (Tatsächlich)
Phase
- Phase 4
Kontakte und Standorte
Studienorte
-
-
-
Cork, Irland
- Cork University Hospital
-
Dublin, Irland
- Mater Misericordiae University Hospital
-
-
-
-
-
London, Vereinigtes Königreich, W2 1NY
- Imperial College Healthcare NHS Trust
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Inclusion Criteria:
- HIV-1 infected males or females
- Between 18 and 65 years of age
- Signed informed consent
Currently receiving a stable antiretroviral regimen comprising of:
- two licensed NRTIs including abacavir and/or didanosine
- any licensed boosted protease inhibitor at any dose (excluding tipranavir*)
- Undetectable plasma HIV RNA to less than 50 copies/mL for at least 24 weeks prior to screening
- Availability of stored plasma with which to perform a tropism assay
- CCR5 tropic HIV virus based on a tropism assay from a stored plasma sample
- Willing to continue unchanged, or to modify antiretroviral therapy, in accordance with the randomisation assignment
- No documented viral resistance to currently licensed HIV-1 protease inhibitors based either on previous HIV-1 genotypic resistance testing or in the judgement of the study investigators
- No previous exposure to maraviroc or CCR5 receptor antagonists
- Subjects in good health upon medical history, physical exam, and laboratory testing in the opinion of the investigator
Female subjects who are heterosexually active and of childbearing potential (i.e., not surgically sterile or at least two years post menopausal) must avoid becoming pregnancy as follows from screening through completion of the study using one or both of the following methods:
- barrier contraceptives (condom, diaphragm with spermicide)
- IUD PLUS a barrier contraceptive
- Female subjects of childbearing potential must have a negative pregnancy test
Exclusion Criteria:
- failure of current antiretroviral regimen due to virological failure
- active opportunistic infection, malignancy or significant co-morbidities in the opinion of the investigator
- pregnancy
- current prohibited concomitant medication (as listed in section 4.1.4)
- no available stored plasma sample predating their current antiretroviral regimen upon which a tropism assay can be performed
- active HBV infection as evidenced by positive hepatitis B surface antigen
- active hepatitis C virus infection as evidenced by positive HCV PCR or HCV antibody.
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Behandlung
- Zuteilung: Zufällig
- Interventionsmodell: Parallele Zuordnung
- Maskierung: Keine (Offenes Etikett)
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
---|---|
Experimental: Immediate switch
|
Maraviroc 150 mg bid
maraviroc 150 mg bid switch 12 weeks later
|
Aktiver Komparator: Continue current antiretroviral therapy
|
Maraviroc 150 mg bid
maraviroc 150 mg bid switch 12 weeks later
|
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Zeitfenster |
---|---|
Mean change from baseline in platelet reactivity between treatment arms at week 12
Zeitfenster: 48 weeks
|
48 weeks
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Zeitfenster |
---|---|
To assess for the following: Mean change over 24 weeks and mean difference at week 12 between study groups in plasma inflammatory and cardiac biomarkers and markers of immune activation
Zeitfenster: 48 weeks
|
48 weeks
|
Mitarbeiter und Ermittler
Sponsor
Mitarbeiter
Ermittler
- Hauptermittler: Alan Winston, MBChB, Imperial College London
- Hauptermittler: Patrick Mallon, MBChB, UCD School of Medicine and Medical Sciences
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Tatsächlich)
Primärer Abschluss (Tatsächlich)
Studienabschluss (Tatsächlich)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Schätzen)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Zusätzliche relevante MeSH-Bedingungen
- RNA-Virusinfektionen
- Viruserkrankungen
- Infektionen
- Durch Blut übertragene Infektionen
- Übertragbare Krankheiten
- Sexuell übertragbare Krankheiten, viral
- Sexuell übertragbare Krankheiten
- Lentivirus-Infektionen
- Retroviridae-Infektionen
- Immunologische Mangelsyndrome
- Erkrankungen des Immunsystems
- HIV-Infektionen
- Molekulare Mechanismen der pharmakologischen Wirkung
- Antiinfektiva
- Antivirale Mittel
- Anti-HIV-Agenten
- Antiretrovirale Mittel
- HIV-Fusionsinhibitoren
- Virale Fusionsprotein-Inhibitoren
- CCR5-Rezeptorantagonisten
- Maraviroc
Andere Studien-ID-Nummern
- 1.0 18.6.2009
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .
Klinische Studien zur HIV-Infektionen
-
Duke UniversityAbgeschlossenCentral Line-associated Bloodstream Infection (CLABSI)Vereinigte Staaten
-
Catholic University of the Sacred HeartAbgeschlossenCentral Line-associated Bloodstream Infection (CLABSI)
-
Abbott Medical DevicesThoratec CorporationAbgeschlossenDriveline Heart-assisted Device Related InfectionVereinigte Staaten
-
Princess Maxima Center for Pediatric OncologyUMC Utrecht; Dutch Cancer SocietyRekrutierungCentral Line-associated Bloodstream Infection (CLABSI)Niederlande
-
University of MalayaTeleflexRekrutierungCLABSI – Central Line Associated Bloodstream InfectionMalaysia
-
National Taiwan University Hospital Hsin-Chu BranchAbgeschlossenCentral Line-associated Bloodstream Infection (CLABSI)
-
Johns Hopkins UniversityAbgeschlossenCLABSI – Central Line Associated Bloodstream InfectionVereinigte Staaten
-
National Taiwan University HospitalAbgeschlossenCentral Line-associated Bloodstream Infection (CLABSI)Taiwan
-
University of ZurichNoch keine RekrutierungCentral Line-associated Bloodstream Infection (CLABSI) | Katheterbedingte Blutstrominfektion
-
Princess Anna Mazowiecka Hospital, Warsaw, PolandNutricia FoundationAktiv, nicht rekrutierendWachstumsfehler | CLABSI – Central Line Associated Bloodstream InfectionPolen
Klinische Studien zur Maraviroc
-
Abramson Cancer Center of the University of PennsylvaniaAbgeschlossenTransplantation hämatopoetischer Stammzellen | Graft-versus-Host-Krankheit
-
ViiV HealthcarePfizerNicht länger verfügbar
-
Kirby InstituteAbgeschlossenHerzkreislauferkrankungArgentinien, Australien, Deutschland, Thailand
-
International Partnership for Microbicides, Inc.Zurückgezogen
-
International Partnership for Microbicides, Inc.AbgeschlossenHIV-InfektionenVereinigte Staaten
-
ViiV HealthcarePfizerAbgeschlossenMenschlicher ImmunschwächevirusVereinigte Staaten, Kanada, Spanien, Belgien, Frankreich, Vereinigtes Königreich, Italien, Brasilien, Puerto Rico, Deutschland, Griechenland
-
International Partnership for Microbicides, Inc.National Institute of Allergy and Infectious Diseases (NIAID); National Institutes...Abgeschlossen
-
University of Maryland, BaltimoreMerck Sharp & Dohme LLCAbgeschlossen
-
Fundación Pública Andaluza para la gestión de la...Abgeschlossen
-
University Of PerugiaAbgeschlossenEntzündung | Atherosklerose | Herz-Kreislauf-Risikofaktor | HIV-Infektion mit anderen BedingungenItalien